Table 1.

New therapies in CRPC.

Trial	Agent	Control arm	CRPC population	Benefit
TAX327 (Tannock et al., 2004; Berthold et al., 2008)	Docetaxel	Mitoxantrone + prednisone	Chemo-naïve	Survival benefit (19.2 vs. 16.3)
IMPACT (Kantoff et al., 2010a)	Sipuleucel-T	Placebo	Chemo-naïve (>80%)	Survival benefit (25.8 vs. 21.7)
TROPIC (de Bono et al., 2010)	Cabazitaxel	Mitoxantrone + prednisone	Docetaxel-refractory	Survival benefit (15.1 vs. 12.7)
COU-AA-301 (de Bono et al., 2011)	Abiraterone	Placebo + prednisone	Docetaxel-refractory	Survival benefit (14.8 vs. 10.9)
ALSYMPCA (Parker et al., 2012b)	Radium-223	Placebo	Docetaxel-refractory	Survival benefit (14.9 vs. 11.3)